BIOMAT Database Logo BIOMAT Database Logo

Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate. 1988

C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Division of Product Safety Assessment, G. D. Searle & Co., Skokie, IL 60077.

The metabolic fates of potassium canrenoate (PC) and spironolactone (SP) were compared for the rat in vivo and in vitro. Approximately 18% of an in vivo dose of SP was metabolized to canrenone (CAN) and related compounds in the rat. In vitro, 20-30% of SP was dethioacetylated to CAN and its metabolites by rat liver 9000 g supernatant (S9). Thus, the major route of SP metabolism is via pathways that retain the sulfur moiety in the molecule. PC was metabolized by rat hepatic S9 to 6 alpha, 7 alpha- and 6 beta, 7 beta-epoxy-CAN. The beta-epoxide was further metabolized to its 3 alpha- and 3 beta-hydroxy derivatives as well as its glutathione (GSH) conjugate. Both 3 alpha- and 3 beta-hydroxy-6 beta, 7 beta-epoxy-CAN were shown to be direct acting mutagens in the mouse lymphoma assay, whereas 6 alpha, 7 alpha- and 6 beta, 7 beta-epoxy-CAN were not. These mutagenic metabolites, their precursor epoxides and their GSH conjugates were not formed from SP under identical conditions. The above findings appear to be due to inhibition of metabolism of CAN formed from SP by SP and/or its S-containing metabolites, since the in vitro metabolism of PC by rat hepatic microsomes was appreciably reduced in the presence of SP. The hypothesized mechanism(s) for this inhibition is that SP and its S-containing metabolites specifically inhibit an isozyme of hepatic cytochrome P-450 or SP is a preferred substrate over PC/CAN for the metabolizing enzymes. Absence of the CAN epoxide pathway in the metabolism of SP provides a possible explanation for the observed differences in the toxicological profiles of the two compounds.

UI MeSH Term Description Entries
D008297 Male Males
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D009153 Mutagens Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. Clastogen,Clastogens,Genotoxin,Genotoxins,Mutagen
D011245 Pregnadienes Pregnane derivatives containing two double bonds anywhere within the ring structures.
D002191 Canrenoic Acid A synthetic pregnadiene derivative with anti-aldosterone activity. Canrenoate Potassium,Potassium Canrenoate,17-Hydroxy-3-Oxo-17alpha-Pregna-4,6-Diene-21-Carboxylic Acid,Kalium-Can.-Ratiopharm,SC-14266,Soldactone,Soludactone,Spiroctan,17 Hydroxy 3 Oxo 17alpha Pregna 4,6 Diene 21 Carboxylic Acid,Acid, 17-Hydroxy-3-Oxo-17alpha-Pregna-4,6-Diene-21-Carboxylic,Acid, Canrenoic,Canrenoate, Potassium,Kalium Can. Ratiopharm,SC 14266,SC14266
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001646 Bile An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum. Biliary Sludge,Sludge, Biliary
D013148 Spironolactone A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827) Spirolactone,Aldactone,Aldactone A,Aquareduct,Duraspiron,Espironolactona Alter,Espironolactona Mundogen,Flumach,Frumikal,Jenaspiron,Novo-Spiroton,Practon,SC-9420,Spiractin,Spiro L.U.T.,Spiro Von Ct,Spirobeta,Spirogamma,Spirolang,Spirono-Isis,Spironone,Spirospare,Veroshpiron,Verospiron,Verospirone,Ct, Spiro Von,Novo Spiroton,NovoSpiroton,SC 9420,SC9420,Spirono Isis,Von Ct, Spiro

Related Publications

C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Spironolactone and potassium canrenoate metabolism.
January 1985, Lancet (London, England),
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
[Action of spironolactone and potassium canrenoate].
December 1990, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Gynaecomastia after spironolactone and potassium canrenoate.
March 1986, Lancet (London, England),
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Spironolactone and potassium canrenoate in normal man.
August 1976, Clinical pharmacology and therapeutics,
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Pharmacokinetics of spironolactone and potassium canrenoate in humans.
March 1985, Journal of pharmacobio-dynamics,
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.
January 1974, Naunyn-Schmiedeberg's archives of pharmacology,
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
September 1985, Lancet (London, England),
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.
October 1987, Gastroenterology,
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
January 1974, European journal of clinical pharmacology,
C S Cook, and C L Hauswald, and G L Schoenhard, and C E Piper, and A Patel, and F M Radzialowski, and J D Hribar, and W Aksamit, and P Finnegan, and R H Bible
Lymphocyte function tests in cirrhotic patients under treatment with spironolactone and potassium canrenoate.
January 1988, The Journal of international medical research,
Copied contents to your clipboard!